Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The closing price of Werewolf Therapeutics Inc (NASDAQ: HOWL) was $2.03 for the day, down -0.98% from the previous closing price of $2.05. In other words, the price has decreased by -$0.98 from its previous closing price. On the day, 1.12 million shares were traded. HOWL stock price reached its highest trading level at $2.15 during the session, while it also had its lowest trading level at $1.96.
Ratios:
Our analysis of HOWL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.30 and its Current Ratio is at 5.30. In the meantime, Its Debt-to-Equity ratio is 0.90 whereas as Long-Term Debt/Eq ratio is at 0.80.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, JMP Securities on April 03, 2024, initiated with a Mkt Outperform rating and assigned the stock a target price of $12.
On August 24, 2023, Wedbush started tracking the stock assigning a Outperform rating and target price of $9.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 12 ’25 when RA CAPITAL MANAGEMENT, L.P. bought 320,913 shares for $0.86 per share. The transaction valued at 275,985 led to the insider holds 6,021,969 shares of the business.
RA CAPITAL MANAGEMENT, L.P. bought 162,539 shares of HOWL for $159,288 on May 14 ’25. The Director now owns 6,237,482 shares after completing the transaction at $0.98 per share. On May 13 ’25, another insider, RA CAPITAL MANAGEMENT, L.P., who serves as the Director of the company, bought 52,974 shares for $0.98 each. As a result, the insider paid 51,915 and bolstered with 6,074,943 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HOWL now has a Market Capitalization of 92829872 and an Enterprise Value of 52379868.
Stock Price History:
The Beta on a monthly basis for HOWL is 0.76, which has changed by 0.07407403 over the last 52 weeks, in comparison to a change of 0.1719923 over the same period for the S&P500. Over the past 52 weeks, HOWL has reached a high of $4.18, while it has fallen to a 52-week low of $0.60. The 50-Day Moving Average of the stock is 38.56%, while the 200-Day Moving Average is calculated to be 60.20%.
Shares Statistics:
HOWL traded an average of 458.24K shares per day over the past three months and 1509280 shares per day over the past ten days. A total of 45.34M shares are outstanding, with a floating share count of 33.92M. Insiders hold about 25.83% of the company’s shares, while institutions hold 34.32% stake in the company. Shares short for HOWL as of 1757894400 were 822835 with a Short Ratio of 1.80, compared to 1755216000 on 982023. Therefore, it implies a Short% of Shares Outstanding of 822835 and a Short% of Float of 2.53.
Earnings Estimates
. The current market rating for Werewolf Therapeutics Inc (HOWL) reflects the collective analysis of 4.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.41, with high estimates of -$0.33 and low estimates of -$0.53.
Analysts are recommending an EPS of between -$1.51 and -$1.74 for the fiscal current year, implying an average EPS of -$1.57. EPS for the following year is -$1.28, with 4.0 analysts recommending between -$0.8 and -$1.62.
